Table 4 Blood pressure and heart rate changes and vasopressor requirement in patients receiving spinal anesthesia
|  | COVID-19 ( +) | COVID-19 (-) | p-value |
|---|---|---|---|
| Â | 24 | 24 | Â |
Baseline MAP, median [IQR] | 89.5 [82.0, 104.2] | 91.0 [84.0, 101.0] | 0.721 |
Drop in MAP, n (%) | 23 (96) | 23 (96) |  > .999 |
 Less than 20% | 3 (13) | 6 (25) | 0.599 |
 More than 20% | 20(83) | 17(71) | 0.49 |
 20–30% | 5(21) | 5(21) |  > 0.99 |
 30–40% | 8 (33) | 8(33) |  > 0.99 |
  > 40% | 7(29) | 4 (17) | 0.546 |
ARV2 of MAP (variability of MAP), median [IQR] | 163.64 [76.79, 266.66] | 124.75 [63.4, 182.62] | 0.344 |
Baseline heart rate, median [IQR] | 92.5 [81.0, 100.0] | 91.0 [80.8, 100.8] | 0.974 |
Decrease in heart rate, n (%) | 15 (62) | 16 (67) |  > .999 |
Percent decrease in heart rate | |||
 Less than 20% | 4 (17) | 2 (8) |  |
 20–30% | 6 (25) | 7 (29) | 0.99 |
 30–40% | 3 (12) | 6 (25) |  |
  > 40% | 2 (8) | 1 (4) |  |
Increase in heart rate, n (%) | 13 (54) | 13 (54) | 0.288 |
Percent increase in heart rate | |||
 Less than 20% | 4 (17) | 4 (17) |  |
 20–30% | 5 (21) | 5 (21) |  |
 30–40% | 1 (4) | 3 (12) |  |
  > 40% | 3 (12) | 1 (4) |  |
Vasopressors required, n (%) | 13 (54) | 9 (38) | 0.387 |
 Phenylephrine, n (%) | 11 (45.8) | 10 (42) |  |
 Total dose, median [IQR] | 300 [225, 450] | 350[225, 550] |  |
 Ephedrine, n (%) | 7 (29.1) | 0 (0) |  |
 Total dose, median [IQR] | 10 [10, 15] | 0 [0,0] |  |